Aster Capital Management (Difc) LTD Dyne Therapeutics, Inc. Transaction History
Aster Capital Management (Difc) LTD
- $262 Billion
- Q4 2024
A detailed history of Aster Capital Management (Difc) LTD transactions in Dyne Therapeutics, Inc. stock. As of the latest transaction made, Aster Capital Management (Difc) LTD holds 18 shares of DYN stock, worth $252. This represents 0.0% of its overall portfolio holdings.
Number of Shares
18Holding current value
$252% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding DYN
# of Institutions
214Shares Held
103MCall Options Held
135KPut Options Held
435K-
Atlas Venture Life Science Advisors, LLC8.02MShares$112 Million31.16% of portfolio
-
Black Rock Inc. New York, NY7.39MShares$103 Million0.01% of portfolio
-
Janus Henderson Group PLC London, X07.38MShares$103 Million0.09% of portfolio
-
Vanguard Group Inc Valley Forge, PA6.7MShares$93.9 Million0.0% of portfolio
-
Ra Capital Management, L.P. Boston, MA6.38MShares$89.4 Million2.43% of portfolio
About Dyne Therapeutics, Inc.
- Ticker DYN
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 51,765,400
- Market Cap $725M
- Description
- Dyne Therapeutics, Inc., a muscle disease company, operates as a biotechnology company that focuses on advancing therapeutics for genetically driven muscle diseases in the United States. It develops various programs for myotonic dystrophy type 1, duchenne muscular dystrophy, and facioscapulohumeral dystrophy, as well as rare skeletal muscle, and...